Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Roche and privately held Atavistik Bio signed a drug-discovery deal potentially worth nearly $2 billion to develop oral treatments for cardiovascular, kidney and metabolic diseases. Atavistik will receive $70 million upfront and could earn up to $1.9 billion in milestone payments, plus royalties.
1. Deal payments and scope
Atavistik said it will receive $70 million upfront and could receive up to $1.9 billion in research, development and commercial milestone payments, plus royalties on sales of approved drugs. The partnership covers multiple drug targets, but the companies did not disclose their number or provide development timelines.
2. Research responsibilities
Atavistik will lead early discovery and research using its technology to identify hidden pockets on disease-causing proteins. Roche will handle further lab and human testing, regulatory filings and commercialization. Atavistik will continue developing treatments for rare blood disorders, including hereditary hemorrhagic telangiectasia.
